Table 1.

Primary efficacy and safety endpoints in patients with NSTE‐ACS and NSTEMI in the TRITON‐TIMI 38 and PLATO trials

	Event rate	HR (95% CI)	P	ARRa	RRRb	NNTc	NNHc
NSTE‐ACS population
Primary efficacy endpointd
TRITON	Prasugrel: 9.30% Clopidogrel: 11.23%	0.82 (0.73‐0.93)	0.0015	1.93%	17.2%	52	—
PLATO	Ticagrelor: 10.0% Clopidogrel: 12.3%	0.83 (0.74‐0.93)	0.0013	2.3%	18.7%	43	—
CV death
TRITON	Prasugrel: 1.78% Clopidogrel: 1.83%	0.98 (0.73‐1.31)	0.8853	0.05%	2.7%	2000	—
PLATO	Ticagrelor: 3.7% Clopidogrel: 4.9%	0.77 (0.64‐0.93)	0.0070	1.2%	24.5%	83	—
MI
TRITON	Prasugrel: 7.26% Clopidogrel: 9.46%	0.76 (0.66‐0.87)	0.0001	2.20%	23.3%	45	—
PLATO	Ticagrelor: 6.6% Clopidogrel:7.7%	0.86 (0.74‐0.99)	0.0419	1.1%	14.3%	91	—
Stroke
TRITON	Prasugrel: 0.97% Clopidogrel: 0.91%	1.07 (0.71‐1.60)	0.7481	−0.06%	−6.6%	—	1667
PLATO	Ticagrelor: 1.3% Clopidogrel: 1.4%	0.95 (0.69‐1.33)	0.79	0.1%	7.1%	1000	—
Primary safety endpointe
TRITON	Prasugrel: 2.16% Clopidogrel: 1.55%	1.40 (1.05‐1.88)	0.0223	−0.61%	−39.4%	—	164
PLATO	Ticagrelor: 13.4% Clopidogrel: 12.6%	1.07 (0.95‐1.19)	0.26	−0.8%	−6.3%	—	125
NSTEMI population
Primary efficacy endpointd
TRITON	Prasugrel: 9.5% Clopidogrel: 11.2%	0.85 (0.73‐0.97)	0.019	1.7%	15.2%	59	—
PLATO	Ticagrelor: 11.4% Clopidogrel: 13.9%	0.83 (0.73‐0.94)	NR	2.5%	18.0%	40	—
Primary safety endpointe
TRITON	Prasugrel: 2.0% Clopidogrel: 1.5%	1.38 (0.97‐1.96)	0.019	−0.5%	−33.3%	—	200
PLATO	Ticagrelor: 14.7% Clopidogrel: 14.3%	1.02 (0.90‐1.15)	NR	−0.4%	−2.8%	—	250

Note: Differences in study design, patient populations and endpoint assessments make cross‐trial comparisons inappropriate.

Abbreviations: AR, absolute risk; ARR, absolute risk reduction; CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction; NNH, number needed to harm; NNT, number needed to treat; NR, not reported; NSTE‐ACS, non‐ST‐segment elevation acute coronary syndrome; NSTEMI, non‐ST‐segment elevation acute coronary syndrome; myocardial infarction; RRR, relative risk reduction.

^aTRITON: event rate in clopidogrel group minus event rate in prasugrel group; PLATO: event rate in clopidogrel group minus event rate in ticagrelor group.

^bARR divided by event rate in clopidogrel group.

^c1 divided by ARR. TRITON: per 450 days; PLATO: per 360 days.

^dCV death, MI, stroke.

^eTRITON: non‐CABG related TIMI major bleeding; PLATO: major bleeding study criteria were bleeding leading to clinically significant disability, or bleeding either associated with a drop in the hemoglobin level of 3 to 5 g/dL or requiring transfusion of 2 to 3 units of red cells.